When precision editing isn’t precise enough: the hidden risk of unintended edits in base editing

From correcting pathogenic variants to disrupting gene function and engineering increasingly complex cell therapies, base editing offers a remarkably versatile way to make targeted genetic changes without relying on double-strand DNA breaks.

As those therapeutic possibilities expand, so does the opportunity to make editing more precise. High on-target efficiency tells only part of the story. Bystander edits, off-target activity and spurious deamination contribute additional sequence changes whose functional consequences depend on where they occur and the biology of the therapeutic application.

This comprehensive white paper explores how these unintended edits are a measurable therapeutic safety variable and how modular base editor architectures can help.

Inside, you’ll learn how to:

• Choose nuclease and deaminase combinations that favor a more precise editing profile
• Tune deaminase activity to reduce bystander editing while preserving high on-target intended editing
• Use modular base editor assembly to add layers of precision across component selection, dose, and assembly-dependent activity

This comprehensive white paper explains:

• Why non-silent bystander mutations represent a significant risk in your therapeutic editing
• Why conventional editor architectures limit systematic mitigation of unintended edits
• How alternative modular approaches to base editor assembly can derisk your editing strategy

Pin-point™ base editing reagents are available for research use only and are not for diagnostic use or direct administration into humans or animals. The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.